ClinicalTrials.Veeva

Menu
E

Enhancing Care Foundation | Wentworth Hospital

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Islatravir
Doravirine
ISL
Ulonivirine
MK-8591A
MK-8591B-062
DOR

Parent organization

This site is a part of Enhancing Care Foundation

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 8 total trials
Locations recently updated

A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)

Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral...

Enrolling
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Drug: ISL/ULO
Drug: ULO

The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with...

Active, not recruiting
HIV Infection
Drug: DOR/ISL

The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continu...

Active, not recruiting
HIV-1 Infection
Drug: DOR/ISL
Drug: ART

This is a randomized, active-controlled, double-blind clinical study designed to evaluate the antiretroviral activity, safety, and tolerability of do...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: Placebo to DOR/ISL

The safety and tolerability of MK-8591A, a 2-drug fixed dose combination (FDC) of doravirine (100mg) and islatravir (0.75mg) \[DOR/ISL 100 mg/0.75 mg...

Active, not recruiting
HIV-1 Infection
Drug: MK-8591A

Trial sponsors

Merck Sharp & Dohme (MSD) logo
U
I

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems